The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD ... and rapidly improved TD symptoms compared to placebo, reducing ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

Other factors that may contribute to the development of TD include: The treatment of tardive dyskinesia focuses on managing the symptoms and, if possible, reducing the severity of the movements.

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Sam Adams begins each morning the same way. He rolls out of bed and walks over to the west-facing window in his Rainbow Motel ...

Bile reflux gastritis (BRG) is a gastro-intestinal condition especially characterized by the reflux of bile into the stomach, further leading to mucosal inflammation along with various other clinical ...

Although dopaminergic therapy produces significant benefits in the early stages of PD, speech symptoms may show selective resistance to pharmaceutical therapy in patients with a disease history of ...

HIV symptoms vary by the stage of infection, known as acute HIV infection (Stage 1), chronic HIV infection (Stage 2), and AIDS (Stage 3). During primary infection, the symptoms are caused by the virus ...